News »Agilvax Appoints Dr. Brad Vale Former Head of Johnson & Johnson Development Corporation (JJDC) to its Board Of Directors


Albuquerque, NM

July 20th, 2016

Agilvax, Inc. today announced it has appointed Brad Vale, PhD, DVM to its Board of Directors. Dr. Vale is an expert corporate executive in the biotechnology, pharmaceutical and medical device investing arena. His appointment was effective July 20th 2016.

Agilvax, Inc. today announced it has appointed Brad Vale, PhD, DVM to its Board of Directors. Dr. Vale is an expert corporate executive in the biotechnology, pharmaceutical and medical device investing arena. His appointment was effective July 20th 2016.

“Dr. Vale brings a wealth of know-how, network, business and drug development leadership experience,” said Federica Pericle, CEO of Agilvax. “I am excited and pleased that Dr. Vale is joining Agilvax’s board. His experience in aiding companies progress from research and development to commercial success will greatly contribute to the success of the company.”

Dr. Vale stated “I am honored to join this company that is dedicated to improving human health through the development of novel cancer therapeutics and vaccines. I look forward to working together with Agilvax board and management team to execute and deliver the company’s vision.”

Dr. Brad H. Vale, Ph.D., DVM, is the Founder and Chief Executive Officer of Calaveras Creek Capital since 2015. His investment focus has been on biotech and medical device companies. Dr. Vale served as the Head of Johnson & Johnson Development Corporation - JJDC, Inc. from 2012 to 2015. He joined Johnson & Johnson in 1992 and in July 1997 moved to California to establish its Silicon Valley office and has invested in over 30 companies for JJDC, including five that were ultimately acquired by various J&J subsidiaries.

Dr. Vale has been an Independent Director of Nevro Corp. since March 1, 2015. He is a member of the board of directors of Cleveland Clinic Innovations, and on a corporate venture advisory board for Silicon Valley Bank, along with sitting on the boards of several private companies. He serves as Member of the Advisory Board of Windham Ventures.. Dr. Vale. is a published author in the area of medical device development. He holds a Ph.D. in Biomedical Engineering from Iowa State University and a Doctor of Veterinary Medicine (D.V.M.) from Washington State University.

About Agilvax

Agilvax (www.agilvax.com) is a biotechnology company that is developing targeted vaccines and cancer stem cell immunotherapies based on a proprietary virus-like particle (VLP) platform technology. The technology integrates epitope identification and immunogenic presentation in a single platform. The Company was founded in 2011 and has headquarters in Albuquerque, NM and offices in El Paso, TX.


Back to News